Regencell Bioscience Holdings Ltd（RGC）股票分析

$9.590

+0.071 (+0.74%)收盤時

Loading chart…

最高: 10.330
開盤: 10.305
成交量加權均價: 9.58
成交量: 688.21K
市值: 45.81M
最低: 8.830
成交金額: 6.60M
企業價值/稅息折舊攤銷前利潤（TTM）: 0.00

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

www.regencellbioscience.com

AI 分析 of Regencell Bioscience Holdings Ltd (RGC)

買進

Regencell Bioscience Holdings Ltd is a good buy right now due to its recent strong performance, with a 5-day change of +30.48% and a significant increase in trading volume at 688,207 shares, which is 2.44 times the 20-day average. However, the stock has a high RSI of 86.065, indicating it may be overbought in the short term, presenting a risk if the momentum reverses.

分析師評級（15）

買進

9 買進

5 持有

1 賣出

目前: 9.59

最低

—

平均

—

最高

—

查看全部評級

估值指標

Regencell Bioscience Holdings Ltd（RGC）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。

預期本益比

嚴重低估

5 年均值 P/E

0.00

目前P/E

0.00

高估

0.00

低估

0.00

預期 EV/EBITDA

嚴重低估

5 年均值 EV/EBITDA

0.00

目前EV/EBITDA

0.00

高估

0.00

低估

0.00

預期股價營收比

嚴重低估

5 年均值 P/S

0.00

目前P/S

0.00

高估

0.00

低估

0.00

Alphio AI 對 RGC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%RGC

$19.32

情境價格

基

基準

基準 · 50%RGC

$17.51

情境價格

悲

悲觀

悲觀 · 25%RGC

$15.37

情境價格

事件時間軸

2026-10-15 (ET)

12:30:00

Regencell Bioscience Shares Rise 11.7% to $9.06

2026-10-14 (ET)

10:30:00

Regencell Bioscience Stock Rises 8.4% to $8.88

2026-10-13 (ET)

12:30:00

Regencell Bioscience Shares Rise 9% to $7.77

2026-10-08 (ET)

12:30:00

Regencell Bioscience Stock Rises 9.1% to $7.76

2026-07-08 (ET)

12:30:00

Regencell Bioscience Stock Rises 25.2% to $7.45

查看更多事件

資訊

查看更多資訊

RGC 常見問題 —— 由 Alphio AI 解答

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

Regencell Bioscience Holdings Ltd is a good buy right now due to its recent strong performance, with a 5-day change of +30.48% and a significant increase in trading volume at 688,207 shares, which is 2.44 times the 20-day average. However, the stock has a high RSI of 86.065, indicating it may be overbought in the short term, presenting a risk if the momentum reverses.

15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.

社群

分享你對 RGC 的看法

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。